Precise magnitude of hospital markups revealed in the US
A recent study has shed light on the size of markups imposed by hospitals for parenteral cancer drugs in the…
By
A recent study has shed light on the size of markups imposed by hospitals for parenteral cancer drugs in the…
BySeveral reasons specified in the ODAC rejection are specific to the sintilimab BLA.
ByUkraine's health minister Viktor Lyashko pushes for 'business as usual' as Russia invades, but ingenuity and support are needed.
ByAduhelm’s US launch has prompted a new look into what is in store for the Alzheimer’s disease market over the…
ByAs we start 2022, the global market access environment has reached an unprecedented high level of risk.
ByThere may be ways to introduce price control under federal drug programmes by stealth in the absence of state price…
ByTwo years after it received US FDA approval, BeiGene’s Brukinsa (zanubrutinib) has made steady progress around the world.
ByGovernments have used lowered pricing as one strategy to reduce expenditures, among others, and therefore the pharmaceutical industry remains under…
By